These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37631877)

  • 1. Polymeric Delivery Systems as a Potential Vaccine against Visceral Leishmaniasis: Formulation Development and Immunogenicity.
    Silva JGLD; Gonçalves AAM; Oliveira LT; Garcia GM; Batista MA; Mendonça LZ; Viana KF; Sant'Ana RCO; Melo Júnior OAO; Silveira-Lemos D; Dutra WO; Martins-Filho OA; Galdino AS; de Moura SAL; Mosqueira VCF; Giunchetti RC
    Vaccines (Basel); 2023 Jul; 11(8):. PubMed ID: 37631877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
    Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis.
    de Mendonça LZ; Resende LA; Lanna MF; Aguiar-Soares RD; Roatt BM; Castro RA; Batista MA; Silveira-Lemos D; Gomes Jde A; Fujiwara RT; Rezende SA; Martins-Filho OA; Corrêa-Oliveira R; Dutra WO; Reis AB; Giunchetti RC
    Parasit Vectors; 2016 Aug; 9(1):472. PubMed ID: 27577735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis.
    Lopes Valentim Di Paschoale Ostolin T; Rodrigues Gusmão M; Augusto Siqueira Mathias F; Mirelle de Oliveira Cardoso J; Mendes Roatt B; Dian de Oliveira Aguiar-Soares R; Conceição Ruiz J; de Melo Resende D; Cristiane Fortes de Brito R; Barbosa Reis A
    Cell Immunol; 2022 Oct; 380():104592. PubMed ID: 36084402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis.
    Gomes DCO; Souza BLDSC; Schwedersky RP; Covre LP; de Matos Guedes HL; Lopes UG; Ré MI; Rossi-Bergmann B
    Microbes Infect; 2022 Mar; 24(2):104884. PubMed ID: 34487860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-).
    Viana KF; Fiuza JA; Gannavaram S; Dey R; Selvapandiyan A; Bartholomeu DC; da Silveira-Lemos D; Bueno LL; Dutra WO; Fujiwara RT; Nakhasi HL; Giunchetti RC
    Parasit Vectors; 2016 Apr; 9():250. PubMed ID: 27136900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoformulations with
    Ottino J; Leite JC; Melo-Júnior OA; González MAC; Carvalho TF; Garcia GM; Batista MA; Silveira P; Cardoso MS; Bueno LL; Fujiwara RT; Santos RL; Paes PRO; Silveira-Lemos D; Martins-Filho OA; Galdino AS; Chávez-Fumagalli MA; Dutra WO; Mosqueira VCF; Giunchetti RC
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis.
    Salgado CL; Dias EL; Stringari LL; Covre LP; Dietze R; Lima Pereira FE; de Matos Guedes HL; Rossi-Bergmann B; Gomes DCO
    Microbes Infect; 2019; 21(7):328-335. PubMed ID: 30817996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of Leishmania braziliensis antigen-specific CD4+ T, CD8+ T, NK and CD3+CD56+NKT cells in the immunopathogenesis of cutaneous leishmaniasis patients: Cytotoxic, activation and exhaustion profiles.
    Cunha CF; Ferraz-Nogueira R; Costa VFA; Pimentel MIF; Chometon TQ; Lyra MR; Schubach AO; Da-Cruz AM; Bertho AL
    PLoS One; 2020; 15(3):e0229400. PubMed ID: 32203546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis.
    Ribeiro PAF; Dias DS; Novais MVM; Lage DP; Tavares GSV; Mendonça DVC; Oliveira JS; Chávez-Fumagalli MA; Roatt BM; Duarte MC; Menezes-Souza D; Ludolf F; Tavares CAP; Oliveira MC; Coelho EAF
    Cytokine; 2018 Nov; 111():131-139. PubMed ID: 30142534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis.
    Zhang J; He J; Liao X; Xiao Y; Liang C; Zhou Q; Chen H; Zheng Z; Qin H; Chen D; Chen Q; Li J; Chen J
    Immunobiology; 2021 May; 226(3):152085. PubMed ID: 33910113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden.
    Roatt BM; Aguiar-Soares RD; Reis LE; Cardoso JM; Mathias FA; de Brito RC; da Silva SM; Gontijo NF; Ferreira SA; Valenzuela JG; Corrêa-Oliveira R; Giunchetti RC; Reis AB
    Front Immunol; 2017; 8():217. PubMed ID: 28321217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticles of Chitosan/Poly(D,L-Lactide-Co-Glycolide) Enhanced the Immune Responses of
    Wang Q; Sun X; Huang X; Huang J; Hasan MW; Yan R; Xu L; Song X; Li X
    Int J Nanomedicine; 2021; 16():3125-3139. PubMed ID: 33981142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polylactide Nanoparticles as a Biodegradable Vaccine Adjuvant: A Study on Safety, Protective Immunity and Efficacy against Human Leishmaniasis Caused by Leishmania Major.
    Ayari-Riabi S; Ben Khalaf N; Bouhaouala-Zahar B; Verrier B; Trimaille T; Benlasfar Z; Chenik M; Elayeb M
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live attenuated Leishmania infantum centrin deleted mutant (LiCen
    Zarei Z; Mohebali M; Dehghani H; Khamesipour A; Tavakkol-Afshari J; Akhoundi B; Abbaszadeh-Afshar MJ; Alizadeh Z; Eskandari SE; Asl AD; Razmi GR
    Comp Immunol Microbiol Infect Dis; 2023 Jun; 97():101984. PubMed ID: 37119594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopotentiation of hepatitis B vaccine using biodegradable polymers as an adjuvant.
    Sivakumar SM; Sukumaran N; Nirmala L; Swarnalakshmi R; Anilbabu B; Siva L; Anbu J; Shanmugarajan TS; Ravichandran V
    J Microbiol Immunol Infect; 2010 Aug; 43(4):265-70. PubMed ID: 20688285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.
    Santos DM; Carneiro MW; de Moura TR; Fukutani K; Clarencio J; Soto M; Espuelas S; Brodskyn C; Barral A; Barral-Netto M; de Oliveira CI
    Int J Nanomedicine; 2012; 7():2115-27. PubMed ID: 22619548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis using canine peripheral blood for establishing in vitro conditions for monocyte differentiation into macrophages for Leishmania chagasi infection and T-cell subset purification.
    Viana KF; Aguiar-Soares RD; Roatt BM; Resende LA; da Silveira-Lemos D; Corrêa-Oliveira R; Martins-Filho OA; Moura SL; Zanini MS; Araújo MS; Reis AB; Giunchetti RC
    Vet Parasitol; 2013 Nov; 198(1-2):62-71. PubMed ID: 24018185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Poly(Lactic-
    Athanasiou E; Agallou M; Tastsoglou S; Kammona O; Hatzigeorgiou A; Kiparissides C; Karagouni E
    Front Immunol; 2017; 8():684. PubMed ID: 28659922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.